Skip to content
value.today

Soligenix, Inc.

SNGX
$9 Mmarket cap on Oct 30, 2026-3.9% since Jan 2024
Compare
World rank
#26,155
Revenue
—
For year ending December-2025
Net income
$-11 M
SEC filing
Employees
14
As of December 31, 2025
SEC filing

Soligenix, Inc. in brief

Soligenix, Inc. is a listed company in the Biotechnology industry, based in Princeton, New Jersey, USA. Its market value was $9 M on 30 October 2026, which makes it the 26,155th largest listed company in the world and the 4,331st largest in the USA on this site. It employs about 14 people and Christopher J. Schaber is its chief executive. Its largest product and service lines by sales in 2024 were Grant revenue (100%). Its shares trade under the symbol SNGX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Soligenix, Inc.

We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.

Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the first Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study and agreement from the European Medicines Agency on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease, we began patient enrollment during December 2024 for the second Phase 3 study called “FLASH2” (Fluorescent Light Activated Synthetic Hypericin 2). We anticipate top-line results in the second half of 2026. Upon successful completion of the Phase 3 FLASH2 study, regulatory approval will be sought to support potential commercialization worldwide.

From the company's annual report filed with the US SEC: read the report

Soligenix, Inc. timeline

4 events, 1995–2009
  1. 1995
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 1996
  4. ✎
    Renamed Endorex Corp
    Formerly Immunotherapeutics Inc.
  5. 2001
  6. ✎
    Renamed Dor Biopharma Inc
    Formerly Endorex Corp.
  7. 2009
  8. ✎
    Renamed Soligenix, Inc.
    Formerly Dor Biopharma Inc.

Events of Soligenix, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$10 M$21 M$31 M$41 M2020202120222023202420252026

World rank over time

▼ down 2,276 places since 2020
2020-01-01: #23886#23,88620202021-01-01: #21538#21,53820212022-01-07: #28956#28,95620222022-12-25: #27912#27,91220222023-07-30: #32910#32,91020232024-01-05: #31229#31,22920242026-03-08: #12605#12,60520262026-08-01: #23062#23,06220262026-10-14: #26361#26,36120262026-10-30: #26162#26,1622026

Rank in USA: #4,355 (Jan 2020) · #4,183 (Jan 2021) · #5,180 (Jan 2022) · #5,112 (Dec 2022) · #5,619 (Jul 2023) · #4,534 (Jan 2024) · #2,360 (Mar 2026) · #4,064 (Aug 2026) · #4,293 (Oct 2026) · #4,334 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.6×
Free cash flow yield
-118.8%
Net margin
—
Operating margin
—
Return on equity
-209.5%
Liabilities / assets
42.6%
Net debt
$-8M
Revenue growth
-11.6%
R&D / revenue
394.0%
Profit per employee
$-791 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $5M, net income $-9M$5MFY18Fiscal year ending Dec 2019: revenue $5M, net income $-9M$5MFY19Fiscal year ending Dec 2020: revenue $2M, net income $-18M$2MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-13M$1MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-14M$1MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-6M$1MFY23Fiscal year ending Dec 2024: revenue —, net income $-8M—FY24Fiscal year ending Dec 2025: revenue —, net income $-11M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-12M$-11M—
Dec 2024——$-9M$-8M—
Dec 2023$1M-11.6%$-8M$-6M-731.0%
Dec 2022$1M+15.9%$-14M$-14M-1452.6%
Dec 2021$1M-65.3%$-13M$-13M-1530.5%
Dec 2020$2M-49.0%$-19M$-18M-749.6%
Dec 2019$5M-11.6%$-11M$-9M-202.2%
Dec 2018$5M—$-9M$-9M-169.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-10M$0M$-10M$-2.14—
Dec 2024$-8M——$-4.98—
Dec 2023$-9M——$-12.66—
Dec 2022$-13M——$-4.81—
Dec 2021$-12M——$-4.69—
Dec 2020$-11M——$-0.64—
Dec 2019$-8M——$-0.48—
Dec 2018$-7M——$-0.68—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-3M—Dec ’24Three months to Mar 2025: revenue —, net income $-3M—Mar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-3M—Dec ’25Three months to Mar 2026: revenue —, net income $-3M—Mar ’26Three months to Jun 2026: revenue —, net income $-2M—Jun ’26Three months to Sep 2026: revenue —, net income $-1M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Soligenix, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-12 M
Net income
$-11 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$9 M
Total liabilities
$4 M
Total equity
$5 M

As of December-2025

Top 23 institutional investors in Soligenix, Inc.#

As of Sep 30, 2026
23 institutions held 1.3 M shares (about 5.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 5.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 23 largest institutional investors in Soligenix, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Citadel Advisors LLC628,136+418,629 (+199.82%)2.69%$0 MNov 16, 2026
2XTX Topco Ltd146,074-11,045 (-7.03%)0.63%$0 MNov 16, 2026
3Geode Capital Management, LLC105,616-14,651 (-12.18%)0.45%$0 MNov 6, 2026
4Vanguard Capital Management LLC81,0050 (0.00%)0.35%$0 MNov 13, 2026
5Jane Street Group, LLC62,709-144,783 (-69.78%)0.27%$0 MNov 12, 2026
6StoneX Group Inc.56,709New0.24%$0 MNov 3, 2026
7Vanguard Fiduciary Trust Co53,9140 (0.00%)0.23%$0 MNov 13, 2026
8Renaissance Technologies LLC44,900New0.19%$0 MNov 12, 2026
9Northern Trust Corp38,0460 (0.00%)0.16%$0 MNov 16, 2026
10Virtu Financial LLC19,596-41,307 (-67.82%)0.08%$0 MNov 17, 2026
11Two Sigma Securities, LLC13,066New0.06%$0 MNov 16, 2026
12Citigroup Inc9,961New0.04%$0 MNov 4, 2026
13Morgan Stanley3,5920 (0.00%)0.02%$0 MNov 13, 2026
14UBS Group AG3,355New0.01%$0 MNov 10, 2026
15Wells Fargo & Company/mn1,550New0.01%$0 MNov 16, 2026
16Jones Financial Companies Lllp1,2360 (0.00%)0.01%$0 MNov 13, 2026
17Plante Moran Financial Advisors, LLC2090 (0.00%)0.00%$0 MNov 4, 2026
18Royal Bank Of Canada50 (0.00%)0.00%$0 MNov 16, 2026
19SBI Securities Co., Ltd.20 (0.00%)0.00%$0 MOct 22, 2026
20Jpmorgan Chase & Co1-244 (-99.59%)0.00%$0 MNov 12, 2026
21IFP Advisors, Inc1New0.00%$0 MOct 16, 2026
22Osaic Holdings, Inc.10 (0.00%)0.00%$0 MNov 12, 2026
23Caitong International Asset Management Co., Ltd10 (0.00%)0.00%$0 MOct 29, 2026

Mutual funds holding Soligenix, Inc.#

4 funds hold shares worth $0 M (about 0.8% of the company). Since their previous reports 3 added shares and 0 sold, buying $0 M net.
Mutual funds holding Soligenix, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC76,176$0 M0.33%<0.01%+33%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.81,005$0 M0.35%<0.01%+39%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC14,459$0 M0.06%<0.01%+43%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC8,054$0 M0.03%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Soligenix, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
16
since
Soligenix, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Christopher J. SchaberCHAIRMAN, CEO AND PRESIDENT, DirectorBuy+15,132$1.320$20 K15,511Form 4
filed Christopher J. SchaberCHAIRMAN, CEO AND PRESIDENT, DirectorBuy+20,000$0.440$9 K90,095Form 4
filed Richard StraubeSENIOR VICE PRESIDENT AND CMOBuy+8,000$0.500$4 K8,000Form 4
filed Christopher J. SchaberCHAIRMAN, CEO AND PRESIDENT, DirectorBuy+7,000$0.740$5 K70,095Form 4
filed Jonathan L. GuarinoSenior Vice President and CFOBuy+1,000$0.700$70011,000Form 4
filed Jonathan L. GuarinoSenior Vice President and CFOBuy+10,000$0.710$7 K10,000Form 4
filed Christopher J. SchaberChairman, CEO and President, DirectorBuy+10,000$0.730$7 K63,095Form 4
filed Jerome B. ZeldisDirectorBuy+3,000$0.890$3 K25,917Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Soligenix, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
66,373
0.7% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-16 reverse split ; 1-for-14.93 reverse split

Trading halts

  • 2026-04-28 11:25 UTC, code T3, resumed 12:00 UTC
  • 2025-01-14 14:41 UTC, code LUDP, resumed 14:46 UTC
  • 2025-01-14 14:34 UTC, code LUDP, resumed 14:39 UTC

Fails to deliver

  • : 7,919 shares at $0.37
  • : 3,833 shares at $0.35
  • : 11,933 shares at $0.37
  • : 3,564 shares at $0.36
  • : 25,401 shares at $0.35

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Soligenix, Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-118.8%Free cash flow is -118.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.14 vs -4.98Diluted EPS -2.14 in fiscal 2025 against -4.98 the year before (report's currency).
    • ✓Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against -$18 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-235.5%-235.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.39 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year212.6%Diluted shares up 212.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Soligenix, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Soligenix, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue—0.10.80.90.82.44.65.25.410
Cost of revenue—0.10.70.60.71.83.64.64.38.4
Gross profit——0.10.40.10.51.10.61.12.0
Research and development7.55.23.37.98.2r9.8r8.16.85.54.3
General and administrative4.44.24.56.75.0r4.3r3.53.03.23.4
Operating expenses129.47.81513r19129.78.77.7
Operating income−12−9.4−7.7−14−13r−19−11−9.1−7.6−5.7
Interest and finance income——————0.10.2——
Interest expense and finance costs—————0.0————
Net interest income————−0.9−0.00.1——0.0
Other non-operating income (expense)0.30.8−0.2−0.7−0.3r0.10.60.20.01.9
Income before tax−12−8.7−7.9−15−13−19−10.0−8.9−7.6−3.8
Income tax−0.5−0.4−1.8−1.2−0.9−0.8−0.6—−0.4−0.5
Net income including minority interests−11−8.3−6.1−14−13—————
Net income attributable to shareholders−11−8.3−6.1−14−13−18−9.4−8.9−7.1−3.2
Earnings per share, basic-2.14-4.98-12.66r-4.81-4.69r-0.64-0.48-0.68-1.16-0.93
Earnings per share, diluted-2.14-4.98-12.66r-4.81-4.69r-0.64-0.48-0.68-1.16-1.34
Shares, weighted average (basic)5.21.70.5r2.92.7r27——6.13.5
Shares, weighted average (diluted)5.21.70.5r2.92.7r2719136.13.6
Balance sheet
Cash and cash equivalents7.97.88.41326195.49.07.88.8
Current assets8.88.89.51427197.5109.410
Property, plant and equipment0.00.00.00.00.00.00.00.00.00.0
Right-of-use (leased) assets0.40.10.20.30.10.20.1r0.2r——
Other intangible assets——————0.00.00.10.1
Total assets9.29.09.81427207.8109.510
Accounts payable1.10.71.13.92.92.12.72.11.81.7
Customer deposits————0.31.01.01.01.01.0
Current liabilities3.74.86.2176.36.16.34.23.22.9
Lease liabilities (non-current)0.2—0.10.2——————
Total liabilities3.94.87.31716166.34.2——
Retained earnings−245−234−226−220−206−193−176−166−157−150
Shareholders' equity5.34.12.5−2.5113.71.56.36.37.4
Total liabilities and equity9.29.09.81427207.8109.510
Shares outstanding102.50.6r2.92.9r3122r188.75.5
Cash-flow statement
Depreciation and amortization————0.00.10.10.00.10.1
Share-based compensation0.60.30.40.30.40.40.40.40.50.6
Cash from operating activities−10−8.4−8.6−13−12−11−7.5−7.2−6.5−5.0
Capital expenditure−0.0—————————
Cash from investing activities−0.0——−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Shares issued—————————3.0
Cash from financing activities107.83.70.119254.08.45.68.8
Exchange-rate effect on cash—0.00.0−0.10.10.0−0.0−0.0——
Change in cash0.1−0.6−4.9−137.413−3.61.2−1.03.9
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Soligenix, Inc. sells: revenue by product line, fiscal 2024#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Grant revenue$0 M100%

Business segments

  • Specialized BioTherapeutics$0 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2024

Where Soligenix, Inc. operates: 4 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.

Soligenix, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office3 subsidiaries—
🇨🇦 Canada1 subsidiary—
🇳🇱 Netherlands1 subsidiary—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Soligenix, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.1 M
Christopher J. Schaber
Other top executives, average
$421 K
the CEO earned 2.6× this
$100 invested is now
$1
Soligenix, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Christopher J. Schaber$1.1 M$1.2 M$421 K$1
2024Christopher J. Schaber$833 K$697 K$367 K$2
2023Christopher J. Schaber$700 K$531 K$331 K$4

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Soligenix, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Directors and officers 3 · Material agreement 5 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 4

Soligenix, Inc.: events reported to the SEC
FiledWhat happenedFiling
Bylaws or fiscal year changedShareholder vote8-K
Delisting noticeDirectors and officers8-K
Delisting notice8-K
Material agreement8-K
Delisting notice8-K
Directors and officersShareholder vote8-K
Bylaws or fiscal year changed8-K
Agreement ended8-K
Material agreementNew debt8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Directors and officersShareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Shareholder vote8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 21, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Soligenix, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2017$2 MPrivate placement after listingUnder $2 million6equitySEC
Apr 2013$2 MPrivate placement after listingUnder $2 million1equitySEC
Jun 2010$6 MNo. 4$2 to $10 million46equity, optionsSEC
Feb 2009$5 MNo. 3$2 to $10 million1equitySEC
Jan 2009$2 MNo. 2$2 to $10 million6equity, optionsSEC
Dec 2008$2 MNo. 1Under $2 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Soligenix, Inc. compares in Biotechnology

  • Market cap$9 M · higher than 9% of 726
  • Revenue growth-11.6% · higher than 33% of 438
  • Price / book1.6× · lower than 64% of 534
  • FCF yield-118.8% · higher than 8% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Soligenix, Inc.🇺🇸$9 M——-11.6%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Soligenix, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Soligenix, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Soligenix, Inc.? Suggest a correction